Synapse - Mark Kris

Results (73)

Identification of pretreatment genomic biomarkers and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers

Meeting Abstract

Choudhury, N. J.; Marra, A.; Yang, S. R.; Falcon, C. J.; Heller, G.; Kris, M. G.; Reis-Filho, J. S.; Riely, G. J.; Yu, H. A.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Germline pathogenic variants impact clinicopathology of advanced lung cancer

Journal Article

Mukherjee, S.; Bandlamudi, C.; Hellmann, M. D.; Kemel, Y.; Drill, E.; Rizvi, H.; Tkachuk, K.; Khurram, A.; Walsh, M. F.; Zauderer, M. G.; more...
Cancer Epidemiology Biomarkers and Prevention (2022)

Fulltext@MSK | Save

Immune biomarkers and response to checkpoint inhibition of BRAF(V600) and BRAF non-V600 altered lung cancers

Journal Article

Murciano-Goroff, Y. R.; Pak, T.; Mondaca, S.; Flynn, J. R.; Montecalvo, J.; Rekhtman, N.; Halpenny, D.; Plodkowski, A. J.; Wu, S. L.; Kris, M. G.; more...
British Journal of Cancer (2022)

Fulltext@MSK | Save

Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis

Journal Article

Tanaka, K.; Yu, H. A.; Yang, S.; Han, S.; Selcuklu, S. D.; Kim, K.; Ramani, S.; Ganesan, Y. T.; Moyer, A.; Sinha, S.; more...
Cancer Cell (2021)

Fulltext@MSK | Save

Allele-specific role of ERBB2 in the oncogenic function of EGFR L861Q in EGFR-mutant lung cancers

Journal Article

Sato, H.; Offin, M.; Kubota, D.; Yu, H. A.; Wilhelm, C.; Toyooka, S.; Somwar, R.; Kris, M. G.; Ladanyi, M.
Journal of Thoracic Oncology (2021)

Fulltext@MSK | Save

Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC

Journal Article

Hellmann, M. D.; Nabet, B. Y.; Rizvi, H.; Chaudhuri, A. A.; Wells, D. K.; Dunphy, M. P. S.; Chabon, J. J.; Liu, C. L.; Hui, A. B.; Arbour, K. C.; more...
Clinical Cancer Research (2020)

Fulltext@MSK | Save

Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer

Journal Article

Schoenfeld, A. J.; Chan, J. M.; Kubota, D.; Sato, H.; Rizvi, H.; Daneshbod, Y.; Chang, J. C.; Paik, P. K.; Offin, M.; Arcila, M. E.; more...
Clinical Cancer Research (2020)

Fulltext@MSK | Save

MAPK pathway alterations correlate with poor survival and drive resistance to therapy in patients with lung cancers driven by ROS1 fusions

Journal Article

Sato, H.; Schoenfeld, A. J.; Siau, E.; Lu, Y. C.; Tai, H.; Suzawa, K.; Kubota, D.; Lui, A. J. W.; Qeriqi, B.; Mattar, M.; more...
Clinical Cancer Research (2020)

Fulltext@MSK | Save

HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers

Journal Article

Li, B. T.; Michelini, F.; Misale, S.; Cocco, E.; Baldino, L.; Cai, Y.; Shifman, S.; Tu, H. Y.; Myers, M. L.; Xu, C.; more...
Cancer Discovery (2020)

Fulltext@MSK | Save

A phase II trial of albumin-bound paclitaxel and gemcitabine in patients with newly diagnosed stage IV squamous cell lung cancers

Journal Article

Paik, P. K.; Kim, R. K.; Ahn, L.; Plodkowski, A. J.; Ni, A.; Donoghue, M. T. A.; Jonsson, P.; Villalona-Calero, M.; Ng, K.; McFarland, D.; more...
Clinical Cancer Research (2020)

Fulltext@MSK | Save